Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sanguinarine compound in preparation of drug for preventing and treating caner and pharmaceutical composition

A compound, the technology of sanguinarine, which is applied in the field of application and pharmaceutical composition of sanguinarine compounds in the preparation of drugs for the prevention and treatment of cancer, can solve problems such as complex components of sanguinarine, restrictions on the application of sanguinarine, and toxicity, etc. Achieve the effect of reducing the cost of cancer treatment, a considerable amount of resources, and a wide range

Inactive Publication Date: 2012-11-07
INST OF ZOOLOGY CHINESE ACAD OF SCI +1
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, Boluohui has been widely used as veterinary medicine and biopesticide in breeding production, but the application of Boluohui is limited due to the complex composition and certain toxicity of Boluohui

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sanguinarine compound in preparation of drug for preventing and treating caner and pharmaceutical composition
  • Application of sanguinarine compound in preparation of drug for preventing and treating caner and pharmaceutical composition
  • Application of sanguinarine compound in preparation of drug for preventing and treating caner and pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Various types of cancer cell lines A549, NCI-H1975, HCT-116, SGC-7901, MCF-7 and HepG2 were seeded in 6-well plates at a certain density, and after 24 hours, the cell fusion degree reached 70%- About 80%, A549 cells (0, 5, 10 μM), NCI-H1975 cells (0, 1, 2.5 μM), HCT-116 cells (0, 1, 2.5 μM), SGC cells were treated with different concentrations of SC and ESG, respectively. -7901 cells (0, 1, 2.5 μM), MCF-7 (0, 2.5, 5 μM) and HepG2 cells (0, 2.5, 5 μM) were treated, and after 24 hours, the cells were lysed with 1×SDS Loading Buffer to extract the total protein. The same amount of protein was subjected to Western Blot immunoblotting experiments, and anti-CIP2A (Santa Cruz) and anti-Actin (actin) antibodies (Sigma) were used to perform immunoblotting respectively to detect changes in their expression under drug treatment. The result is as Figure 1-5 As shown, in lung cancer cells A549 and NCI-H1975 ( figure 1 ), colon cancer cells HCT-116 ( figure 2 ), gastric cancer c...

Embodiment 2

[0042] 12 different types of cancer cell lines (A549, NCI-H1975, NCI-H460, HCC827, SPC-A-1, Glc-82, L78, 95D, HCT-116, SGC-7901 , MCF-7 and HepG2 cells) were inoculated in a 96-well plate (about 5000 cells per well, 100 μl medium), cultured (37°C, 5% CO 2 Incubator) 24 hours later, the 12 kinds of cells were treated with SC and ESG compounds with different concentration gradients (1-10 μM). After 44 hours of incubation, 10 μl of 3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg / ml) was added to each well, and the incubation was continued for 4 hours. After the reaction was terminated, the culture medium was sucked off, 150 μl dimethyl sulfoxide was added to each well, shaken at a low speed to fully dissolve, and then the absorbance value at 490 nm (OD490) was measured with a microplate reader. According to the results of growth inhibition rate, the half inhibitory concentration (IC) of SC and ESG to 12 kinds of cells was calculated. 50 ), specif...

Embodiment 3

[0044] Ethoxysanguinarine or sanguinarine citrate and their pharmaceutically acceptable salts or solvates can be prepared into injections after adding water for injection according to conventional methods, finely filtering, potting and sterilizing.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides an application of ethoxy sanguinarine or its pharmaceutically acceptable salt or Sanguinarine citrate in preparation of a drug for preventing and / or treating cancer. Ethoxy sanguinarine or its pharmaceutically acceptable salt or Sanguinarine citrate, as a compound which can effectively lower CIP2A protein and inhibit cancer cell proliferation, has latent advantages of little toxic and side effect, significant effect of inhibiting cancer cell proliferation, broad-spectrum anti-cancer effect, wide source, low cost and the like, and has a wide anticancer application prospect in clinic.

Description

technical field [0001] The invention relates to the use of an active ingredient of a Chinese herbal medicine in the preparation of a drug for preventing and / or treating cancer and a pharmaceutical composition containing the active ingredient. It specifically relates to the use of sanguinarine compounds or salts thereof in preparing medicines for preventing and treating cancer and pharmaceutical compositions containing sanguinarine compounds or salts thereof. Background technique [0002] Cancer has now become the leading cause of death worldwide. About 1 / 8 of the world's population mortality is caused by cancer, exceeding the sum of the deaths from AIDS, tuberculosis and malaria. According to statistics, in 2004, the number of cancer deaths reached 7.4 million (accounting for about 13% of all deaths). It is estimated that there were about 12 million new cancer cases and about 7.6 million cancer deaths in the world in 2007 (an average of 20,000 deaths per day). It is estima...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4741A61P35/00A61P35/02
Inventor 周光飚程永现马亮吕青刘姿
Owner INST OF ZOOLOGY CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com